The Amyloidosis Channel is supported with funding from Prothena (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Selecting patients with AL amyloidosis for autoHSCT
Iuliana Vaxman, MD, Mayo Clinic, Rochester, MN, discusses the role of autologous hematopoietic stem cell transplantation (autoHSCT) in immunoglobulin light-chain (AL) amyloidosis. Dr Vaxman explains that only 20% of patients with AL amyloidosis are eligible for autoHSCT and it is therefore crucial to select the right patients to undergo this treatment. However, there is currently no data outlining patient selection criteria in this setting. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
